RECRUITING

Histiocytic Disorder Follow-up Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

Official Title

Histiocytic Disorder Follow-up Study

Quick Facts

Study Start:2022-09-01
Study Completion:2028-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05915208

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:0 Years to 89 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * diagnosis of histiocytic disorder at any age
  2. 1. Langerhans cell histiocytosis,
  3. 2. Erdheim-Chester disease,
  4. 3. Rosai-Dorfman disease,
  5. 4. Xanthogranuloma,
  6. 5. Mixed histiocytosis
  7. 6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
  8. 7. Hemophagocytic lymphohistiocytosis
  1. * None

Contacts and Locations

Study Contact

Gaurav Goyal, MD
CONTACT
1-866-438-1640
histio@uabmc.edu

Principal Investigator

Gaurav Goyal, MD
PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35233
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

  • Gaurav Goyal, MD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-01
Study Completion Date2028-12

Study Record Updates

Study Start Date2022-09-01
Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

  • survivorship
  • long-term
  • targeted therapy
  • second cancer

Additional Relevant MeSH Terms

  • Histiocytosis
  • Langerhans Cell Histiocytosis
  • Erdheim-Chester Disease
  • Rosai Dorfman Disease
  • Xanthogranuloma
  • Malignant Histiocytoses